AU2002231659A1 - Lithium complexes of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof - Google Patents

Lithium complexes of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof

Info

Publication number
AU2002231659A1
AU2002231659A1 AU2002231659A AU2002231659A AU2002231659A1 AU 2002231659 A1 AU2002231659 A1 AU 2002231659A1 AU 2002231659 A AU2002231659 A AU 2002231659A AU 2002231659 A AU2002231659 A AU 2002231659A AU 2002231659 A1 AU2002231659 A1 AU 2002231659A1
Authority
AU
Australia
Prior art keywords
triscarboxymethyl
tetraazacyclododecane
dihydroxypropyl
hydroxymethyl
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002231659A
Other versions
AU2002231659B2 (en
Inventor
Peter Blaszkiewicz
Holger Hoffmann
Orlin Petrov
Dr. Johannes Platzek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10064467A external-priority patent/DE10064467C2/en
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of AU2002231659A1 publication Critical patent/AU2002231659A1/en
Application granted granted Critical
Publication of AU2002231659B2 publication Critical patent/AU2002231659B2/en
Assigned to BAYER INTELLECTUAL PROPERTY GMBH reassignment BAYER INTELLECTUAL PROPERTY GMBH Request for Assignment Assignors: SCHERING AKTIENGESELLSCHAFT
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

AU2002231659A 2000-12-15 2001-12-05 Lithium complexes of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof Expired AU2002231659B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10064467A DE10064467C2 (en) 2000-12-15 2000-12-15 Lithium complexes of N- (1-hydroxymethyl-2,3-dihydroxypropyl) -1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, their preparation and use
DE10064467,8 2000-12-15
PCT/EP2001/014283 WO2002048119A2 (en) 2000-12-15 2001-12-05 Lithium complexes of n-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof

Publications (2)

Publication Number Publication Date
AU2002231659A1 true AU2002231659A1 (en) 2002-08-29
AU2002231659B2 AU2002231659B2 (en) 2007-07-05

Family

ID=7668584

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002231659A Expired AU2002231659B2 (en) 2000-12-15 2001-12-05 Lithium complexes of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof
AU3165902A Pending AU3165902A (en) 2000-12-15 2001-12-05 Lithium complexes of n-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3165902A Pending AU3165902A (en) 2000-12-15 2001-12-05 Lithium complexes of n-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof

Country Status (35)

Country Link
US (1) US6894151B2 (en)
EP (1) EP1343770B1 (en)
JP (1) JP4399163B2 (en)
KR (1) KR100869627B1 (en)
CN (1) CN1229357C (en)
AR (1) AR035609A1 (en)
AT (1) ATE430737T1 (en)
AU (2) AU2002231659B2 (en)
BG (1) BG66117B1 (en)
BR (1) BR0116219A (en)
CA (1) CA2431976C (en)
CY (1) CY1109280T1 (en)
CZ (1) CZ304573B6 (en)
DE (2) DE10064467C2 (en)
DK (1) DK1343770T3 (en)
EC (1) ECSP034676A (en)
EE (1) EE05245B1 (en)
ES (1) ES2325982T3 (en)
HK (1) HK1064098A1 (en)
HR (1) HRP20030576B1 (en)
HU (1) HU229657B1 (en)
IL (1) IL156432A0 (en)
ME (1) ME00157B (en)
MX (1) MXPA03005240A (en)
NO (1) NO324864B1 (en)
NZ (1) NZ526478A (en)
PL (1) PL204181B1 (en)
PT (1) PT1343770E (en)
RS (1) RS51862B (en)
RU (1) RU2003120513A (en)
SK (1) SK287424B6 (en)
TW (1) TWI302531B (en)
UY (1) UY27056A1 (en)
WO (1) WO2002048119A2 (en)
ZA (1) ZA200305421B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112840A2 (en) * 2003-06-25 2004-12-29 Guerbet Peptide conjugate for magnetic resonance imaging
FR2867473B1 (en) 2004-03-12 2006-06-23 Guerbet Sa PORPHYRINE COMPOUND AND HIGH FIELD USE IN MRI
EP1765812B1 (en) * 2004-07-02 2009-04-29 Bracco Imaging S.p.A Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents
KR20080108989A (en) * 2006-03-14 2008-12-16 말린크로트, 인코포레이티드 Metal complexes of tetraazamacrocycle derivatives
US7777029B2 (en) * 2006-05-02 2010-08-17 San Diego State University (Sdsu) Foundation Bifunctional chelators for sequestering lanthanides
DE102009057274B4 (en) 2009-12-02 2011-09-01 Bayer Schering Pharma Aktiengesellschaft Gadobutrol preparation using trioxobicyclo-octane
WO2011054480A1 (en) 2009-11-09 2011-05-12 Bayer Schering Pharma Aktiengesellschaft Gadobutrol production by means of a ceramic membrane
DE102009053252B3 (en) * 2009-11-09 2011-09-01 Bayer Schering Pharma Aktiengesellschaft Making gadobutrol, to diagnose stroke, comprises e.g. reacting N-(6-hydroxy-2,2-dimethyl-1,3-dioxepan-5-yl)-tetraaza-cyclododecane lithium chloride or bromide complex with haloacetic acid and lithium hydroxide or N-methyl imidazole
DE102010013833A1 (en) 2010-03-29 2011-09-29 Bayer Schering Pharma Aktiengesellschaft Producing gadolinium complex of N-(hydroxymethyl-dihydroxypropyl)-triscarboxymethyl-tetraazacyclododecane useful as magnetic resonance imaging contrast agent, comprises e.g. reacting cyclic compound with dimethylformamide dimethylacetal
DE102010023105A1 (en) 2010-06-04 2011-12-08 Bayer Schering Pharma Aktiengesellschaft Gadobutrol preparation in a one-pot process using DMF-acetal and N-methylimidazole
RS60001B1 (en) 2011-04-21 2020-04-30 Bayer Ip Gmbh Preparation of high-purity gadobutrol
CN106543094A (en) * 2016-11-04 2017-03-29 嘉实(湖南)医药科技有限公司 The preparation method of high-purity gadobutrol
KR101971435B1 (en) * 2017-08-29 2019-04-24 주식회사 엔지켐생명과학 Gadobutrol intermediate and method for preparing gadobutrol using the same
KR102033964B1 (en) * 2018-01-19 2019-10-18 주식회사 엔지켐생명과학 Gadoteridol intermediate and method for preparing gadoteridol using the same
CN111039885B (en) * 2019-12-06 2021-03-05 广州康瑞泰药业有限公司 Method for preparing high-purity combretastatin
KR20210112910A (en) * 2020-03-06 2021-09-15 주식회사 엔지켐생명과학 Method for manufacturing calcobutrol to gadovist excipient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009119A1 (en) * 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-TETRAAZACYCLODODECANE-BUTYLTRIOLS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
DE19724186C2 (en) 1997-06-02 2002-07-18 Schering Ag Process for the mono- and 1,7-bis-N-ß-hydroxyalkylation of cycles and the corresponding N-ß-hydroxyalkyl-1,4,7,10-tetraazacyclododecane-Li salt complexes

Similar Documents

Publication Publication Date Title
AU2002231659A1 (en) Lithium complexes of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof
AU3165902A (en) Lithium complexes of n-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof
AU2465401A (en) Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
AU2002310256A1 (en) Ppp2cs as modifiers of the p53 pathway and methods of use
AU2001277754A1 (en) Proline derivatives and use thereof as drugs
AU2002226486A1 (en) Novel c-glycoside derivatives and use thereof
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
AU2002226487A1 (en) Novel c-glycoside derivatives and use thereof
AU2002223647A1 (en) Aryl-substituted indirubin derivatives, the production thereof and use of the same
AU2001281850A1 (en) Use of inulin and inulin derivatives
AU4923200A (en) Isothiazolecarboxamides and their use as microbicides
AU2002214948A1 (en) Heterocyclylalkyl azole derivatives and use thereof as pesticidal agents
AU2002308891A1 (en) Novel heterocyclic derivatives and medicinal use thereof
PL367676A1 (en) Novel heterocyclic derivatives and medicinal use thereof
AU2001284068A1 (en) Monitoring of patient's electrical characteristics
AU2001235437A1 (en) Isothiazolecarboxylic acid derivatives and their use as microbicides
AU5464901A (en) Dichloropyridyl- and dichloroisothiazolyl-thiocarboxamides and their use as microbicides
AU2002308889A1 (en) Novel heterocyclic compound and medicinal use thereof
HUP0100318A3 (en) Salicyli denaminoalcohol derivatives, their chiral copper complexes, their preparations and use of the latter
AU2001225523A1 (en) Novel arylpropionaldehyde derivatives and production and use of the same
AU2001268903A1 (en) Hexaglucal compound and the use and the methods of preparing them
AU2001282268A1 (en) Phenantridine derivatives and their use as anti-telomerase agent
AU2001255708A1 (en) Synthesis and use of thienotriazolodiazepines
AU2003215688A1 (en) Derivatives of 3,3',5,5'-tetraalkylbenzidine bis {mono-carboxylatobenzenepolycarboxylic} and applications thereof
AU2002316994A1 (en) Gdp-mannose-3',5'-epimerase and methods of use thereof